Early Metabolic Risk in Childhood Brain Cancer Survivors with Childhood-Onset Growth Hormone Deficiency.

Authors

Alice Casiraghi, Olivier Pollé, Clément Bailly, Laura Gonzalez Briceno, François Doz, Brice Fresneau, Franck Bourdeaut, Samuel Abbou, Christelle Dufour, Yassine Bouchoucha, Jacques Grill, Graziella Pinto, Dinane Samara-Boustani, Caroline Thalassinos, Magali Viaud, Adrien Nguyen-Quoc, Sibylle Rovani, Athanasia Stoupa, Kévin Beccaria, Thomas Blauwblomme, Luca Persani, Anne Bachelot, Carine Courtillot, Philippe Touraine, Michel Polak, Dulanjalee Kariyawasam

Published in

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. Jul 04, 2026. Epub Jul 04, 2026.

Abstract

Growth hormone deficiency (GHD) is the earliest and most common pituitary-hormone deficiency in childhood brain cancer (CBC) survivors. To evaluate metabolic and endocrine outcomes in survivors of childhood brain cancer (CBC) (excluding craniopharyngiomas) who received growth hormone (GH) therapy during childhood, following their transition into adulthood.
Observational, multicentric study across 1 paediatric endocrinology, 2 paediatric oncology departments and 1 adult endocrinology department. Ninety-one CBC survivors with childhood-onset GHD, aged ≥18 years in January 2025, with follow-up data available through April 30, 2025, were included. Assessments included lipid profile, HbA1c, bone mineral density (BMD), body mass index (BMI), and pituitary hormone status. Subgroup analyses compared patients with suprasellar (SS) versus non-suprasellar (nSS) tumours and those with persistent adulthood GHD with or without continued GH therapy versus transient GHD. Multivariate analyses were performed.
Median age at last evaluation was 21 years (IQR 19-26). At transition, 71/91 patients (78%) remained GHD. Dyslipidaemia affected 54/91 (59.4%) individuals, prediabetes 9/91 (10%), and reduced BMD (osteopenia or osteoporosis) 62/90 (68.6%). BMI and HbA1C were significantly higher in the SS sub-group than the nSS sub-group. Dyslipidemia was not associated with tumour location. No significant differences among patients with persistent GHD on GH therapy, persistent GHD without therapy, or transient GHD.
Among CBC survivors with childhood-onset GHD, dyslipidaemia, impaired glucose metabolism, and reduced BMD are highly prevalent in very early adulthood. Suprasellar tumours show a distinct metabolic vulnerability.

PMID:
42401204
Bibliographic data and abstract were imported from PubMed on 05 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.